D-0016-2021 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0016-2021 was initiated by Direct Rx on Jan 15, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is terminated (terminated Dec 7, 2020). Affected quantity: a) 54 bottles; b) 26 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 14, 2020
Initiation Date
Jan 15, 2020
Termination Date
Dec 7, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 54 bottles; b) 26 bottles

Product description

Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

FL, GA

Code information

Lots: a) 09AU1911 Exp. 02/28/2022; b) 09SE1904 Exp. 03/31/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0016-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0016-2021. Report a data issue: hello@regdatalab.com.